Home > Sinobiomed Inc. SOBM

Tag: Sinobiomed Inc. SOBM

FridaySep 05, 2008 6:17 pm

Sinobiomed Inc. (SOBM.OB): Chinese Wonder Drug-Maker?

Sinobiomed (SOBM) is a Chinese developer of genetically engineered recombinant protein drugs and vaccines. The company's drugs treat diseases and ailments such as malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration. Sinobiomed currently has 10 products: three on the market, four in clinical trials and three in research and development. Sinobiomed, based in the bustling metropolis of Shanghai, could be on the forefront of the burgeoning Chinese biotechnology industry. China’s biotech industry is expected to continue its rapid expansion of 20 percent to 30 percent annually to $8.5 billion by 2010, helped by…

Continue Reading

TuesdayAug 26, 2008 9:19 am

HotStix Stock of the Week – Sinobiomed Inc. (SOBM.OB)

Sinobiomed Inc. (SOBM.OB) is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Sinobiomed employs a patented, low-cost, high-yield production process to enhance bioactivity and guarantee the highest levels of purity. Sinobiomed currently has 10 products approved or in development: three on the market, four in clinical trials, and three in R&D. The company's products respond to a wide range of diseases and conditions, including hepatitis B&C, surgical bleeding, diabetic ulcers and burns, malaria, cancer, rheumatoid arthritis, acute liver disease, stroke, blood clots and thrombosis, acute pancreatitis, and blood cell regeneration. Sinobiomed has several competitive advantages in…

Continue Reading

ThursdayAug 21, 2008 4:10 am

Vaccine Trials, Uses, Progress for Sinobiomed, Inc. (SOBM.OB)

Sinobiomed’s (OTCBB: SOBM) recombinant Batroxobin (rBAT) is in its Phase IIb trials for 328 patients. Results are expected before year’s end. A company news release says international interest from government and organizations would grow significantly if the product proceeds to Phase III clinical trials. “[We have] already received indications of interest from global pharmaceutical companies for joint development, marketing and production,” the release states. Clinical trials for Sinobiomed’s recombinant malaria candidate vaccine are set to begin before the end of the 3rd Quarter. The tests are tentatively planned to take place at Mahidol University in Bangkok, Thailand. Batroxobin is produced…

Continue Reading

WednesdayJul 02, 2008 12:07 pm

Dutton Associates Featured Company: Sinobiomed Inc. (SOBM.OB)

Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, one awaiting approval, four in clinical trials and three in research and development. The company’s products treat a wide range of diseases and conditions, including malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration. Sinobiomed explains its technology like this: “The process of discovering a new drug involves determining which proteins cause or contribute to problems in the body because they are lacking,…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered

512.354.7000

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .